Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SEL-212 (Selecta Biosciences)
- Development stage
- Unknown
- Lead developer
- Cartesian Therapeutics
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
SEL-212 is a combination therapy designed for the treatment of chronic refractory gout. It consists of two components: pegadricase (SEL-037), a pegylated recombinant yeast-derived uricase enzyme, and ImmTOR (SEL-110), a biodegradable nanoparticle containing the immunosuppressant rapamycin (sirolimus). The pegadricase component works by metabolizing uric acid into allantoin, a highly soluble metabolite that is easily excreted by the kidneys. The ImmTOR component is specifically engineered to mitigate the formation of anti-drug antibodies (ADAs) against pegadricase, which is a common limitation of uricase-based therapies. By inducing immune tolerance, SEL-212 aims to provide sustained reduction in serum uric acid levels and dissolution of urate crystals (tophi). The drug is being developed through a partnership between Selecta Biosciences and Sobi (Swedish Orphan Biovitrum).
- Other names
- ImmTOR + pegadricasepegsiticase + rapamycin nanoparticlepegadricase co-administered with ImmTORpegsiticase
02
Targets
FKBP1AmTOR (Mammalian target of rapamycin kinase)UOX (Urate oxidase)
Beyond the preview
Go deeper on SEL-212 (Selecta Biosciences).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SEL-212 (Selecta Biosciences).